Ozempic Lawsuit in Pennsylvania (GLP-1 Claims)

What Pennsylvania residents should know

Pennsylvania residents with GLP-1 injury claims are generally not limited to Pennsylvania state court. Most filed cases are transferred into the federal multidistrict litigation, MDL-3094, before Judge Karen S. Marston in the Eastern District of Pennsylvania, which held 3,763 pending cases as of June 1, 2026.

Pennsylvania law still matters: the state's filing deadline, damages rules, and procedural law can shape an individual claim even when the case is litigated in the MDL.

Pennsylvania: the home of MDL-3094

Pennsylvania has a distinctive role in this litigation: MDL-3094, the national GLP-1 injury proceeding, is based in the U.S. District Court for the Eastern District of Pennsylvania, so Pennsylvania residents' federal cases are coordinated in their home state once filed in, or transferred to, MDL-3094. On the coverage side, Pennsylvania Medicaid is ending coverage of GLP-1 drugs for the treatment of overweight and obesity effective January 1, 2026. Pennsylvania Attorney General Dave Sunday has also warned consumers about counterfeit GLP-1 drugs and joined a February 2025 multistate letter to the FDA.

Sources: Pennsylvania DHS — Medical Assistance bulletin on obesity treatment agents (Nov. 2025); Philadelphia Inquirer — Pennsylvania warns on counterfeit GLP-1 drugs (June 2025); Multistate attorneys general letter to the FDA on GLP-1 drugs (Feb. 19, 2025).

Possible eligibility factors

• Documented use of a GLP-1 medication (prescription and pharmacy records from Pennsylvania providers).
• A diagnosis such as gastroparesis, ileus, or bowel obstruction — commonly supported by a gastric emptying study, endoscopy, imaging, or hospitalization records.
• Injury timing consistent with medication use.
• Filing within the deadline that applies to the claim under Pennsylvania law.

How Pennsylvania claims proceed

Most Pennsylvania GLP-1 cases are filed in or transferred to MDL-3094 in the Eastern District of Pennsylvania for coordinated proceedings. The court has scheduled Rule 702 expert-admissibility hearings for September 10–18, 2026 (Case Management Order No. 32); bellwether trial dates have not yet been set. Pennsylvania's general personal injury limitations period is 2 years (42 Pa. Cons. Stat. § 5524), but accrual and discovery-rule questions are fact-specific for injuries that develop during ongoing medication use.

What records support Ozempic claims in Pennsylvania?

• Prescription, pharmacy, insurance, or provider records showing Ozempic or another GLP-1 medication and dates of use.
• Emergency room, hospital, gastroenterology, imaging, gastric-emptying, surgery, or follow-up records for the alleged injury.
• Records showing diagnosis timing for gastroparesis, bowel obstruction, ileus, aspiration, or related complications.
• Medication history, dose changes, side-effect reports, provider messages, and documents that help connect use and symptoms.

What exposure and legal context matter in Pennsylvania?

Pennsylvania residents may have been prescribed Ozempic, Wegovy, Rybelsus, Saxenda, Mounjaro, Zepbound, or Trulicity through endocrinologists, primary care practices, weight-management clinics, telehealth services, or hospital systems across the state.

Where are Pennsylvania Ozempic cases handled?

Living in Pennsylvania does not necessarily mean the case will be filed only in Pennsylvania. Claims may be evaluated by national firms, filed in federal court, coordinated through MDL proceedings, or handled through another legal process.

Federal courts in Pennsylvania

• Eastern District of Pennsylvania
• Middle District of Pennsylvania
• Western District of Pennsylvania

What is the filing deadline for Ozempic lawsuits in Pennsylvania?

For a Pennsylvania resident researching Ozempic claims, the starting point is usually Pennsylvania's general personal injury period: 2 years under 42 Pa. Cons. Stat. § 5524. That is only a starting point, not a final legal deadline for every person.

The real filing deadline can depend on diagnosis date, when the injury and possible cause were discovered, exposure location, wrongful-death issues, prior claim paperwork, and whether the case is filed directly, transferred to an MDL, or handled through another process.

Discovery-rule note: Pennsylvania applies a discovery rule that can delay accrual until the injury and its cause reasonably could have been discovered.

How long do Pennsylvania residents have to file?

Pennsylvania's personal injury statute of limitations applicable to product liability claims is 2 years (42 Pa. Cons. Stat. § 5524). Accrual timing, tolling, and repose periods can still change the real deadline in an individual case.

• Filing period: 2 years — 42 Pa. Cons. Stat. § 5524.
• Discovery rule: Pennsylvania applies a discovery rule that can delay accrual until the injury and its cause reasonably could have been discovered.

Because the controlling deadline depends on diagnosis date, discovery facts, exposure history, wrongful-death rules, and how the claim is filed, only a licensed attorney can confirm the deadline that applies to a specific situation. This page is general legal information, not legal advice.

What should Pennsylvania residents ask a lawyer?

• Which GLP-1 medication and injury records do you need for an initial review?
• Do I need a gastric-emptying study, hospitalization record, imaging report, or specialist diagnosis?
• How do the Rule 702 schedule and lack of bellwether trial dates affect current claim review?
• How do state filing deadlines apply to my medication and symptom timeline?
• Would my claim be handled locally, nationally, or through the MDL?
• Are there upfront costs?